Non-Small Cell Lung Cancer

Latest News
January 1st 2025

AI in Oncology: Opportunities and Challenges for NSCLC

December 27th 2024

ICYMI: Highlights From WCLC 2024

December 23rd 2024

Precision Oncology in NSCLC: Overcoming Patient Selection Barriers

December 20th 2024

Top 5 NSCLC Content for 2024

December 19th 2024

Ensartinib Receives FDA Approval for ALK-Positive Locally Advanced or Metastatic NSCLC

Video Interviews
View All
January 11th 2025

How Early Detection, Precision Medicine Can Impact Lung Cancer Outcomes

January 5th 2025

Combining Liquid and Tissue Biopsies for Better Lung Cancer Care

January 1st 2025

Revolutionizing Lung Cancer Care: The Impact of Liquid Biopsies

December 13th 2024

Next-Gen Strategies for Resistance in EGFR-Mutated Lung Cancer

December 4th 2024

Optimizing Outcomes in NSCLC With Precision Medicine and Teamwork

November 28th 2024

Revolutionizing NSCLC Care With Circulating Tumor DNA and MRD Assays

November 13th 2024

Perioperative Strategies in NSCLC: Future Directions and Challenges

November 2nd 2024

Balancing Benefits and Risks of Amivantamab

September 9th 2024

EMPOWER-Lung 1 Trial Data Showcase Promise of Cemiplimab in NSCLC

September 5th 2024

Dr Ticiana Leal on Recent Advancements in Perioperative NSCLC Care

More News

Syringe and vials | Image credit: Aliaksandr Marko – stock.adobe.com
December 17th 2024

FDA Rejects Subcutaneous Amivantamab for NSCLC Over Manufacturing Concerns

Hayden E. Klein
Subcutaneous amivantamab joins a growing list of drugs receiving complete response letters due to manufacturing facility issues.
Lungs | image credit: istock photo
December 13th 2024

Updated Data Show Zongertinib Yields Responses in 71% With Previously Treated HER2-Mutated NSCLC

Mary Caffrey
The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.
Bhuvana Sagar, MD
December 9th 2024

What Do Liquid Biopsies Add to Value-Based Cancer Care?

Hayden E. Klein
Payers want to make sure patients are getting biopsies done so they can get on the right therapies, said Bhuvana Sagar, MD, Oncology Consultants.
FDA approval with stamp | Image Credit: Surendra - stock.adobe.com
December 5th 2024

Zenocutuzumab Approved for NRG1+ NSCLC and Pancreatic Adenocarcinoma

Laura Joszt, MA
The accelerated approval was based on the results of the eNRGy trial of 64 patients with NRG1-positive non–small cell lung cancer and 30 patients with NRG1-positive pancreatic adenocarcinoma.
Immunotherapy | Image Credit: © kentoh-stock.adobe.com
December 2nd 2024

Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC

Maggie L. Shaw
Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.
Lungcancertreatment | Image Credit: © Vitalii Vodolazskyi-stock.adobe.com
November 27th 2024

Durvalumab Underutilization Highlights Gaps in NSCLC Treatment Strategies

Maggie L. Shaw
Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients who have unresectable stage III non–small cell lung cancer (NSCLC).
Martin Dietrich, MD, PhD
November 21st 2024

Research Priorities Evolve With Amivantamab's Broader NSCLC Indications

Maggie L. Shaw
In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat non–small cell lung cancer (NSCLC).
FDA | Image Credit: © Artur-stock.adobe.com
November 18th 2024

FDA Approves Companion Diagnostic for Tepotinib in MET Exon 14 mNSCLC

Ashling Wahner
The FDA approved the FoundationOne Liquid CDx to identify patients with metastatic non–small cell lung cancer (mNSCLC) with MET exon 14 skipping alterations who may be eligible for tepotinib (Tepmetko; EMD Serono).
Lung cancer | Image Credit: © Crystal light - stock.adobe.com
November 15th 2024

Tailored Management Needed for Male Patients With NSCLC After Surgery

Maggie L. Shaw
Lung cancer is the top cause of cancer-related death worldwide.
Lung cancer image | Image Credit: © appledesign-stock.adobe.com
November 8th 2024

Sunvozertinib NDA Submitted to FDA for NSCLC

Chris Ryan
A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non–small cell lung cancer (NSCLC).
Biomarker Scrabble tiles | Image Credit: © lexiconimages-stock.adobe.com
October 30th 2024

Improving Early-Stage Lung Cancer Care

Maggie L. Shaw
More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery.
Martin Dietrich, MD, PhD
October 24th 2024

Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib

Maggie L. Shaw
Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Umit Tapan, MD, Boston Medical Center
October 18th 2024

Expanding Access to NSCLC Innovations: Challenges and Opportunities

Maggie L. Shaw
The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.
FDA approved | Image Credit: © wladimir1804 -stock.adobe.com
October 16th 2024

FDA Approves Optune Lua Device in NSCLC

Maggie L. Shaw
Optune Lua creates tumor-treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors or docetaxel to treat metastatic non–small cell lung cancer (NSCLC) that has not responded to platinum-based treatment.
Emory Winship Cancer Institute | Image: Emory
October 14th 2024

In Cancer Care, Innovation Comes at a Cost

Rose McNulty
Ticiana Leal, MD, Emory Winship Cancer Institute
October 12th 2024

Early Biomarker Testing Key for Perioperative NSCLC Success

Rose McNulty Maggie L. Shaw
Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer (NSCLC).
LC and breathing | Image Credit: © Cozine-stock.adobe.com
October 10th 2024

Breathomics: A Low-Cost Solution for Early Lung Cancer Diagnosis?

Kimberly Rath, PharmD
Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals.
FDA Approval | Image Credit: © BHM-stock.adobe.com
October 4th 2024

Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA

Maggie L. Shaw
The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable non–small cell lung cancer (NSCLC) in the neoadjuvant and adjuvant settings.
Joshua K. Sabari, MD, NYU Langone
September 30th 2024

Amivantamab Presents an Exciting Treatment Opportunity in NSCLC

Maggie L. Shaw
In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals from the FDA for use in non–small cell lung cancer (NSCLC).
Martin Dietrich, MD, PhD, Cancer Care Centers of Brevard
September 27th 2024

Amivantamab Accolades Add Up for NSCLC

Maggie L. Shaw
On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor its fourth approval overall.
FDA | Image Credit: © wladimir1804-stockk.adobe.com
September 26th 2024

FDA Approves Osimertinib in Stage III NSCLC

Maggie L. Shaw
The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutation.
AI generated lungs and doctor | Image credit: PRASANNAPIX - stock.adobe.com
September 20th 2024

FDA Approves Amivantamab for EGFR-Positive NSCLC With Exon 19 Deletion, Exon 21 L858R Substitution

Skylar Jeremias
The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).
David P. Carbone, MD, PhD, The Ohio State University
September 16th 2024

Liquid Biopsy Advances: Vital Role in Biomarker Testing in Lung Cancer

Maggie L. Shaw
Here we conclude our discussion with David P. Carbone, MD, PhD, The Ohio State University, by addressing the importance of both advocacy for and education on biomarker testing in the lung cancer space.
Sparkling telomere | Image Credit: Dr_Microbe - stock.adobe.com
September 13th 2024

THIO Combo Yields Survival Benefit in Advanced NSCLC

Russ Conroy
Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial later this year.
Joshua K. Sabari, MD, NYU Langone
August 30th 2024

Novel Mechanisms Set FDA-Approved Amivantamab-Lazertinib Combo Apart in NSCLC

Maggie L. Shaw
This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.
Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
August 27th 2024

Measuring the Magnitude of Systemic Inflammatory Response in NSCLC

Julia Bonavitacola
Measures of systemic inflammation used for the liver, including C-reactive protein-albumin ratio and modified Glasgow prognostic score, demonstrated prognostic value in non–small cell lung cancer (NSCLC).
David P. Carbone, MD, PhD, The Ohio State University
August 23rd 2024

Beyond Early Stage: Biomarker Testing's Role in Advanced Lung Cancer

Maggie L. Shaw
In part 1 of our interview with David P. Carbone, MD, PhD, The Ohio State University, he addressed why it is important to conduct biomarker testing in both lung cancer overall and non–small cell lung cancer more specifically.
FDA Approved
August 20th 2024

Lazertinib With Amivantamab Approved by FDA for Use in NSCLC

Julia Bonavitacola
Patients with non-small cell lung cancer (NSCLC) can use lazertinib in combination with amivantamab as a first-line treatment.
A panel of 4 experts on lung cancer
August 19th 2024

Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Mark Socinski, MD John Heymach, MD, PhD Wade Iams, MD Sandip P. Patel, MD
The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.
brain and lungs | Image Credit: magicmine-stock.adobe.com
August 15th 2024

ICIs Extend Survival in Older Patients With NSCLC, Brain Metastases

Maggie L. Shaw
This investigation was conducted among older, frail patients, a population typically underrepresented in clinical trials.
1234>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo